COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Price, Quote, News and Overview
NASDAQ:COLL - Nasdaq - US19459J1043 - Common Stock - Currency: USD
COLL Quote, Performance and Key Statistics
COLLEGIUM PHARMACEUTICAL INC
NASDAQ:COLL (2/4/2025, 8:00:00 PM)
After market: 30.93 0 (0%)30.93
-0.27 (-0.87%)
The current stock price of COLL is 30.93 USD. In the past month the price increased by 4.81%. In the past year, price decreased by -7.62%.
COLL Latest News, Press Releases and Analysis
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation.
Collegium Provides 2025 Financial Guidance and Business Update
Collegium Provides 2025 Financial Guidance and Business Update
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – –...
Collegium to Participate in Upcoming Investor Conferences
Collegium Reports Record Third Quarter 2024 Financial Results
Collegium Reports Record Third Quarter 2024 Financial Results
– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER...
COLL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 81.23 | 784.20B | ||
| JNJ | JOHNSON & JOHNSON | 15.36 | 369.55B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 28.01 | 366.85B | ||
| MRK | MERCK & CO. INC. | 11.88 | 229.54B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.1 | 213.85B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.32 | 210.86B | ||
| PFE | PFIZER INC | 8.32 | 146.61B | ||
| SNY | SANOFI-ADR | 13.51 | 134.13B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 50.53 | 119.91B | ||
| ZTS | ZOETIS INC | 29.9 | 77.71B | ||
| GSK | GSK PLC-SPON ADR | 8.42 | 71.08B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 30.98 | 42.23B |
Related stock screener links
About COLL
Company Profile
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 197 full-time employees. The company went IPO on 2015-05-07. The firm commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.
Company Info
COLLEGIUM PHARMACEUTICAL INC
100 Technology Center Dr
Stoughton MASSACHUSETTS 02072 US
CEO: Joseph Ciaffoni
Employees: 197
Company Website: https://www.collegiumpharma.com/
Investor Relations: https://ir.collegiumpharma.com
Phone: 17817133699
COLL FAQ
What is the stock price of COLL?
The current stock price of COLL is 30.93 USD.
What is the symbol for COLLEGIUM PHARMACEUTICAL INC stock?
The exchange symbol of COLLEGIUM PHARMACEUTICAL INC is COLL and it is listed on the Nasdaq exchange.
On which exchange is COLL stock listed?
COLL stock is listed on the Nasdaq exchange.
Is COLL a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for COLL, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of COLL.
Does COLL stock pay dividends?
COLL does not pay a dividend.
When does COLL stock report earnings?
COLL will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of COLL?
The PE ratio for COLL is 5.62. This is based on the reported non-GAAP earnings per share of 5.5 and the current share price of 30.93 USD.
What is the Short Interest ratio of COLL stock?
The outstanding short interest for COLL is 17.7% of its float.
COLL Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to COLL. When comparing the yearly performance of all stocks, COLL is a bad performer in the overall market: 72.66% of all stocks are doing better.
COLL Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to COLL. COLL scores excellent on profitability, but there are concerns on its financial health.
COLL Financial Highlights
Over the last trailing twelve months COLL reported a non-GAAP Earnings per Share(EPS) of 5.5. The EPS increased by 3566.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.78% | ||
| ROA | 5.42% | ||
| ROE | 37.82% | ||
| Debt/Equity | 3.43 |
COLL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to COLL. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 434.25% and a revenue growth 11.41% for COLL